Tolerability of one hour 10mg/kg infliximab infusions in patients with inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 7, Issue 2, 2013, Pages 129-133

  Babouri, Abdenour ^a   Buisson, Anthony ^a   Bigard, Marc André ^a   Peyrin Biroulet, Laurent ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Acute reactions; Delayed reactions; Inflammatory bowel disease; Infliximab; One hour infusions

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; AZATHIOPRINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG TOLERABILITY; FAINTNESS; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; PARESTHESIA; PRIORITY JOURNAL; PSORIASIS; PUVA; RASH; STEROID THERAPY; ULCERATIVE COLITIS; CLASSIFICATION; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

MLCS; MLOWN;

EID: 84872499309     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.03.007     Document Type: Article

References (17)

1. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
2. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
3. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
4. Sands B.E., Blank M.A., Patel K., van Deventer S.J. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004, 2:912-920.
5. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
6. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
7. Buch M.H., Bryer D., Lindsay S., Rees-Evans B., Fairclough A., Emery P. Shortening infusion times for infliximab administration. Rheumatology (Oxford) 2006, 45:485-486.
8. Breynaert C., Ferrante M., Fidder H., Van Steen K., Noman M., Ballet V., et al. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterol 2011, 106:778-785.
9. Van Assche G., Vermeire S., Noman M., Amant C., Weyts E., Vleminckx A., et al. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. J Crohns Colitis 2010, 4:329-333.
10. REMICADE SPC Read on Aug 17, 2011. http://www.medicines.org.uk/emc/medicine/3236.
11. Cheifetz A., Smedley M., Martin S., Reiter M., Leone G., Mayer L., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003, 98:1315-1324.
12. Peyrin-Biroulet L., Oussalah A., Williet N., Pillot C., Bresler L., Bigard M.-A. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011, 60:930-936.
13. Williet N., Pillot C., Oussalah A., Billioud V., Chevaux J.-B., Bresler L., et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis 2011.
14. Peyrin-Biroulet L., Pillot C., Oussalah A., Billioud V., Aissa N., Balde M., et al. Urinary tract infections in hospitalized inflammatory bowel disease patients: a 10-year experience. Inflamm Bowel Dis 2011.
15. Fidder H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
16. van Vollenhoven R.F., Gullström E., Klareskog L. Feasibility of 1 hour infliximab infusions. Ann Rheum Dis 2005, 64:654.
17. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.